研究キーワード (4件):
Apoptosis
, DNA Repair
, DNA修復
, アポトーシス
競争的資金等の研究課題 (9件):
2014 - 2017 進行大腸癌におけるレゴラフェニブ治療に対する階層的分子マーカーの探索
1999 - 2003 DNA修復機構によるアポトーシス誘導に関する研究
1999 - 2003 Study on apoptotic reaction induced by DNA repair system
1995 - 1999 Functional assay for HNPCC
1995 - 1999 遺伝性非腺腫症性大腸癌の機能的遺伝子診断法の開発
家族性腫瘍の遺伝子診断に関する研究
Research on DNA repair
DNA修復に関する研究
Research on genetic diagnosis for familial cancer
全件表示
論文 (53件):
Shin Takahashi, Kota Ouchi, Yasuhiro Sakamoto, Takahiro Mori, Hideki Shimodaira, Masahiro Takahashi, Hisatsugu Ohori, Chieko Kudo, Yoshikazu Takahashi, Hiroo Imai, et al. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201. Journal of Gastrointestinal Oncology. 2023. 14. 2. 676-691
Takashi Yoshioka, Masanobu Takahashi, Yasuhiro Sakamoto, Akira Okita, Tadahisa Fukui, Yasuko Murakawa, Yoshiaki Shindo, Hiroo Imai, Hisatsugu Ohori, Hidekazu Shirota, et al. Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial. Anticancer research. 2022. 42. 4. 2009-2015
Masanobu Takahashi, Yasuhiro Sakamoto, Hisatsugu Ohori, Yasushi Tsuji, Michio Kuroki, Satoshi Kato, Kazunori Otsuka, Keigo Komine, Masahiro Takahashi, Shin Takahashi, et al. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers. Cancer Chemotherapy and Pharmacology. 2021. 88. 3. 393-402
Masanobu Takahashi, Yasuhiro Sakamoto, Kazunori Otsuka, Mariko Kanbe, Hisatsugu Ohori, Yoshiaki Shindo, Hiroshi Honda, Ken Saijo, Kota Ouchi, Yasuko Murakawa, et al. Phase ii study of the reuse of trastuzumab with docetaxel beyond progression after first-line treatment in second-line treatment for unresectable, metastatic gastric cancer (T-core1203). Tohoku Journal of Experimental Medicine. 2021. 254. 1. 49-55
Phase II intermittent (or stop and go) l-OHP administration of first-line bevacizumab (BV) plus mFOLFOX6 or CapeOX therapies in Japanese patients with mCRC: The interim report of T-CORE0901.
(American Society of Clinical Oncology 2012 Gastrointestinal Cancers Symposium 2012)
Phase II intermittent (or stop and go) l-OHP administration of first-line bevacizumab (BV) plus mFOLFOX6 or CapeOX therapies in Japanese patients with mCRC: The interim report of T-CORE0901.
(American Society of Clinical Oncology 2012 Gastrointestinal Cancers Symposium 2012)